Drs Lempert and Kushner1 question a number of decisions made in designing our randomized trial of patching vs atropine in children aged 3 to younger than 7 years with moderate amblyopia. We have previously answered similar questions from Dr Lempert both in press and in private communication.2-4 The design of any randomized clinical trial requires a number of decisions regarding which treatments to compare and which outcome measures to use. Those decisions are made in light of the specific questions being asked and current understanding of the disease.
Repka MX, Wallace DK, Beck RW, et al. Contradictions in the Amblyopia Treatment Studies—Reply. Arch Ophthalmol. 2006;124(2):285–287. doi:10.1001/archopht.124.2.285-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.